MET
MIM.164860 7q31
Pathology
germline mutations in familial papillary renal carcinoma (MIM.605074)
somatic mutations in sporadic papillary renal carcinoma (MIM.605074)
somatic mutations in childhood type hepatocellular carcinoma (MIM.114550)
References
Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, Lae M, Fisher DE, Ladanyi M. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007 Feb 1;67(3):919-29. PMID: 17283122
Chen Y, Takita J, Mizuguchi M, Tanaka K, Ida K, Koh K, Igarashi T, Hanada R, Tanaka Y, Park MJ, Hayashi Y. Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosomes Cancer. 2007 Apr;46(4):348-58. PMID: 17243166
Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med. 2005 Jun;11(6):284-92. PMID: 15949770
Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med. 2004 Dec;4(8):855-68. PMID: 15579033
Rosario M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 2003 Jun;13(6):328-35. PMID: 12791299